Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)
Condition: Erosive Esophagitis Interventions: Drug: DWP14012 Xmg; Drug: DWP14012 Xmg placebo; Drug: Esomeprazole 40mg; Drug: Esomeprazole 40mg placebo Sponsor: Daewoong Pharmaceutical Co. LTD. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acid Reflux | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Research | Study